Home › Funds › Euclidean Capital LLC › FHTX

Euclidean Capital LLC position in FHTX

FOGHORN THERAPEUTICS INC · Health Care

Euclidean Capital LLC reported holding 1,573,761 shares of FHTX (FOGHORN THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$7.7M, representing 1.75% of its reported portfolio and ranking #6 among its reported holdings. Euclidean Capital LLC has disclosed FHTX holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)1.57M sh
Reported value held$7.68M
Portfolio Weight1.75%
First reportedQ3 2023
Last changeHold
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Euclidean Capital LLC's FHTX position evolved

Euclidean Capital LLC first disclosed a stake in FHTX in Q3 2023 at 1,573,761 shares (US$7.9M). The position peaked in Q3 2024 at 1,573,761 shares, worth US$14.7M. Across 12 filings, Euclidean Capital LLC held the position steady without any share-count change. The most recent filing (Q2 2026) shows 1,573,761 shares valued at US$7.7M.

Quarter by quarter

QuarterSharesValueChange
Q3 2023 1.57M $7.87M New
Q4 2023 1.57M $10.15M Hold
Q1 2024 1.57M $10.56M Hold
Q2 2024 1.57M $9.05M Hold
Q3 2024 1.57M $14.65M Hold
Q4 2024 1.57M $7.43M Hold
Q1 2025 1.57M $5.74M Hold
Q2 2025 1.57M $7.40M Hold
Q3 2025 1.57M $7.70M Hold
Q4 2025 1.57M $8.50M Hold
Q1 2026 1.57M $7.52M Hold
Q2 2026 1.57M $7.68M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About FHTX and 13F data

FHTX (FOGHORN THERAPEUTICS INC) is a Health Care company. 35 other funds we track also report a position in FHTX — the largest reported positions include Flagship Pioneering, LLC (US$61.8M), BVF INC/IL (US$28.5M), Birchview Capital, LP (US$1.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding FHTX

All FHTX fund holders →

FAQ

How long has Euclidean Capital LLC held FHTX?

Euclidean Capital LLC has disclosed FHTX holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

What is Euclidean Capital LLC's current position in FHTX?

As of Q2 2026, Euclidean Capital LLC holds 1.57M shares of FHTX (FOGHORN THERAPEUTICS INC), valued at $7.68M, representing 1.75% of its reported portfolio and ranking #6.

Has Euclidean Capital LLC been buying or selling FHTX?

In the latest 13F filing (Q2 2026), Euclidean Capital LLC held unchanged its position in FHTX. The position peaked in Q3 2024 at 1.57M shares.

Which other funds hold FHTX?

Other major institutional holders of FHTX include Flagship Pioneering, LLC, BVF INC/IL, Birchview Capital, LP, among 35 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.